ijerph-logo

Journal Browser

Journal Browser

Second Edition of Gynecological Cancer

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Women's Health".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 22117

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
2. Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan
Interests: clinical trial; minimally invasive surgery; gynecological cancer; fertility-preservation surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Last year, I had the great honor of receiving an invitation from the Editors of the International Journal of Environmental Research and Public Health to become the Guest Editor for the Special Issue “Gynecological Cancer”, in which 18 articles have finally been published. I appreciate your valuable contribution. Due to advances in modern technology, the use of next-generation whole genomic sequences and precise medicine has become much plausible in the treatment of patients with various kinds of gynecological cancers. Additionally, much evidence supports the significant therapeutic effects of targeted therapy and/or immunotherapy in the management of women with gynecological cancers, especially for those patients who are believed to have died of such diseases before. This 2nd edition of the Special Issue welcomes articles on these and other themes focusing on the treatment of various kinds of gynecological cancers.

Prof. Dr. Peng-Hui Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • gynecological cancer
  • ovarian cancer
  • precise medicine
  • uterine cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (6 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 330 KiB  
Article
Sexual Dysfunction among Gynaecological Cancer Survivors: A Descriptive Cross-Sectional Study in Malaysia
by Akmal Muzamir Mohamad Muhit, Luke Sy-Cherng Woon, Nik Sumayyah Nik Mhd Nor, Hatta Sidi, Aida Hani Mohd Kalok, Nirmala @ Chandralega Kampan and Mohamad Nasir Shafiee
Int. J. Environ. Res. Public Health 2022, 19(23), 15545; https://doi.org/10.3390/ijerph192315545 - 23 Nov 2022
Cited by 4 | Viewed by 1908
Abstract
Background: Sexual dysfunction is a major issue among gynaecological cancer survivors. This study aimed to evaluate the prevalence of sexual dysfunction among survivors of gynaecological cancer in Malaysia and to determine its risk factors. Methods: A cross-sectional study was conducted of 116 married [...] Read more.
Background: Sexual dysfunction is a major issue among gynaecological cancer survivors. This study aimed to evaluate the prevalence of sexual dysfunction among survivors of gynaecological cancer in Malaysia and to determine its risk factors. Methods: A cross-sectional study was conducted of 116 married women with gynaecological cancer who attended the gynaeoncology and oncology clinics at Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Sociodemographic and clinical data were collected. Sexual dysfunction was measured using the Malay Version Female Sexual Function Index (MVFSFI). Univariate and multivariate logistic regression analyses were used to determine the risk factors of female sexual dysfunction. Results: The prevalence of sexual dysfunction among gynaecological cancer survivors was 60% (70 out of 116). Sexual dissatisfaction was the most prevalent domain of sexual dysfunction at 68.1%. Sexual dysfunction was significantly associated with low education levels (Primary level, AOR = 4.92, 95% CI: 1.12–21.63; secondary level, AOR = 4.06, 95% CI: 1.14–14.44). Non-Malays were significantly more likely to have sexual dysfunction compared with Malays (AOR = 3.57, 95% CI: 1.16–11.06). In terms of treatment, combinations of surgery and radiotherapy (AOR = 4.66, 95% CI: 1.01–21.47) as well as surgery and chemoradiation (AOR = 5.77, 95% CI: 1.20–27.85) were considered. Conclusions: Gynaecological cancer survivors with lower education levels, non-Malay ethnicity, and receiving treatment combinations of surgery and radiotherapy or surgery and chemoradiation have a higher risk of sexual dysfunction. A holistic approach in managing the various sociocultural and clinical issues is required to prevent sexual dysfunction among these patients. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
10 pages, 1476 KiB  
Article
Awareness and Knowledge of HPV, HPV Vaccination, and Cervical Cancer among an Indigenous Caribbean Community
by Zachary Claude Warner, Brandon Reid, Priscilla Auguste, Winnie Joseph, Deanna Kepka and Echo Lyn Warner
Int. J. Environ. Res. Public Health 2022, 19(9), 5694; https://doi.org/10.3390/ijerph19095694 - 7 May 2022
Cited by 8 | Viewed by 3262
Abstract
Caribbean women experience a cervical cancer incidence rate that is three times higher than that among their North American counterparts. In this study, we performed a needs assessment of the knowledge and awareness of HPV, HPV vaccination, and cervical cancer and receipt of [...] Read more.
Caribbean women experience a cervical cancer incidence rate that is three times higher than that among their North American counterparts. In this study, we performed a needs assessment of the knowledge and awareness of HPV, HPV vaccination, and cervical cancer and receipt of cervical cancer screening among an indigenous Caribbean community. We purposively recruited individuals aged ≥18 from a community health care clinic (n = 58) to complete a 57-item structured interview including items on demographics, cancer history, knowledge and awareness of HPV, HPV vaccines, cervical cancer, and cervical cancer screening. Participants’ mean age was 47.1 years (SD: 14.4). Most were female (74.1%), were married/partnered (51.7%), had primary education (63.8%), and identified as Kalinago (72.4%). Whereas 79.5% had heard of cervical cancer, few had heard of HPV (19.6%) or the HPV vaccine (21.8%). Among those who knew someone with cancer, 90.9% had heard of the HPV vaccine, compared with only 9.1% of those who did not know anyone with cancer (p = 0.02). Access to HPV vaccination is an immediate, cost-effective cancer prevention priority for reducing the disproportionate burden of HPV-related cancers, particularly cervical cancer, in the Caribbean. We recommend culturally targeted education interventions to improve knowledge about HPV vaccination and the link between HPV and cervical cancer. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
Show Figures

Figure 1

9 pages, 958 KiB  
Article
Diagnosis of Peritoneal Tuberculosis from Primary Peritoneal Cancer
by I-Hui Chen, Pao-Ling Torng, Chia-Yi Lee, Kuang-Han Lee, Heng-Cheng Hsu and Wen-Fang Cheng
Int. J. Environ. Res. Public Health 2021, 18(19), 10407; https://doi.org/10.3390/ijerph181910407 - 3 Oct 2021
Cited by 5 | Viewed by 2903
Abstract
Peritoneal tuberculosis (PTB) is an uncommon extrapulmonary infection mimickng primary peritoneal cancer (PPC). We retrospectively included 23 women with PTB and 47 women with PPC treated in a medical center to study the clinical and radiological features that differentiate PTB from PPC. Body [...] Read more.
Peritoneal tuberculosis (PTB) is an uncommon extrapulmonary infection mimickng primary peritoneal cancer (PPC). We retrospectively included 23 women with PTB and 47 women with PPC treated in a medical center to study the clinical and radiological features that differentiate PTB from PPC. Body temperature above 38 °C was a unique feature of PTB (34.7% versus 0%, p < 0.001). Body Mass Index (BMI) was lower (21.9 ± 3.7 versus 25.2 ± 4.1, p = 0.003), white blood cell (WBC) count was lower (5179.6 ± 1502.2 versus 7716.2 ± 2741.8, p < 0.001), and CA-125 level was lower (508.0 ± 266.1 versus 2130.1 ± 2367.2 U/mL, p < 0.001) in PTB compared with PPC. Imaging detected more pulmonary infiltration and consolidation (52.2% versus 6.4%, p < 0.001), and less omental/mesentery changes (52% versus 83%, p < 0.001) in PTB compared with PPC. The operated patients received earlier treatment compared to patients without operation (7.9 ± 5.3 days versus 17.2 ± 11.0 days, p = 0.010). In conclusion, fever above 38 °C, lower BMI, lower WBC count, less elevated CA-125 level, and imaging of less omental involvement were features of PTB differentiated from PPC. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
Show Figures

Figure 1

13 pages, 891 KiB  
Article
Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study
by Hsin-Ying Huang, Chun-Ju Chiang, Yun-Yuan Chen, San-Lin You, Heng-Cheng Hsu, Chao-Hsiun Tang and Wen-Fang Cheng
Int. J. Environ. Res. Public Health 2021, 18(12), 6629; https://doi.org/10.3390/ijerph18126629 - 20 Jun 2021
Cited by 2 | Viewed by 2676
Abstract
We aimed to evaluate factors influencing the outcomes of patients with platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Patients with advanced-stage EOC, who received debulking surgery and adjuvant chemotherapy for recurrence, were obtained from the National Health Insurance Research database of Taiwan between 2000 [...] Read more.
We aimed to evaluate factors influencing the outcomes of patients with platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Patients with advanced-stage EOC, who received debulking surgery and adjuvant chemotherapy for recurrence, were obtained from the National Health Insurance Research database of Taiwan between 2000 and 2013. A total of 1038 patients with recurrent advanced-stage EOC were recruited. The platinum + paclitaxel (PT) group had the best five-year overall survival (OS) compared with the other three groups (p < 0.001). The hazard ratios (HRs) of five-year OS for the platinum + liposomal doxorubicin (PD), topotecan (TOP), and pegylated liposomal doxorubicin (PLD) groups were 1.21 (p = 0.07), 1.35 (p = 0.016), and 1.80 (p < 0.001), respectively, compared with the PT group. The PT group also had lower hazard ratios of five-year OS for patients with platinum therapy-free interval (TFIp) between 6 and 12 months compared with the other three groups (p < 0.0001). However, the HRs of five-year OS did not differ between the PT and PD groups in patients with TFIp >12 months. Patients with TFIp >12 months had lower HRs of five-year OS compared with those with TFIp of 6–12 months, regardless of whether they were treated with platinum-based (p = 0.001) or non-platinum-based (p = 0.003) regimens. Chemotherapeutic regimens and TFIp influenced the outcomes of patients with recurrent EOC. For patients with TFIp of 6–12 months, the PT regimen is the first choice based on their best overall survival result. For patients with TFIp >12 months, either platinum-based or non-platinum regimens could be used because of their similar excellent overall survival. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
Show Figures

Figure 1

Review

Jump to: Research, Other

23 pages, 1118 KiB  
Review
Barriers to and Facilitators of Cervical Cancer Screening among Women in Southeast Asia: A Systematic Review
by Brandon Chua, Viva Ma, Caitlin Asjes, Ashley Lim, Mahsa Mohseni and Hwee Lin Wee
Int. J. Environ. Res. Public Health 2021, 18(9), 4586; https://doi.org/10.3390/ijerph18094586 - 26 Apr 2021
Cited by 29 | Viewed by 8094
Abstract
In Southeast Asia, cervical cancer is the second most common cancer in women. Low coverage for cervical cancer screening (CCS) becomes a roadblock to disease detection and treatment. Existing reviews on CCS have limited insights into the barriers and facilitators for SEA. Hence, [...] Read more.
In Southeast Asia, cervical cancer is the second most common cancer in women. Low coverage for cervical cancer screening (CCS) becomes a roadblock to disease detection and treatment. Existing reviews on CCS have limited insights into the barriers and facilitators for SEA. Hence, this study aims to identify key barriers and facilitators among women living in SEA. A systematic literature review was conducted on Pubmed, Embase, PsycINFO, CINAHL, and SCOPUS. Primary qualitative and quantitative studies published in English that reported barriers and facilitators to CCS were included. The Mix Methods Appraisal Tool was used for the quality assessment of the included studies. Among the 93 included studies, pap smears (73.1%) were the most common screening modality. A majority of the studies were from Malaysia (35.5%). No studies were from Timor-Leste and the Philippines. The most common barriers were embarrassment (number of articles, n = 33), time constraints (n = 27), and poor knowledge of screening (n = 27). The most common facilitators were related to age (n = 21), receiving advice from healthcare workers (n = 17), and education status (n = 11). Findings from this review may inform health policy makers in developing effective cervical cancer screening programs in SEA countries. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
Show Figures

Figure 1

Other

Jump to: Research, Review

10 pages, 1632 KiB  
Systematic Review
Sentinel Lymph Node Biopsy in Surgical Staging for High-Risk Groups of Endometrial Carcinoma Patients
by Antonio Raffone, Diego Raimondo, Antonio Travaglino, Giulia Rovero, Manuela Maletta, Ivano Raimondo, Marco Petrillo, Giampiero Capobianco, Paolo Casadio, Renato Seracchioli and Antonio Mollo
Int. J. Environ. Res. Public Health 2022, 19(6), 3716; https://doi.org/10.3390/ijerph19063716 - 21 Mar 2022
Cited by 4 | Viewed by 2297
Abstract
Background: In endometrial carcinoma (EC) patients, sentinel lymph node (SLN) biopsy has shown the potential to reduce post-operative morbidity and long-term complications, and to improve the detection of low-volume metastasis through ultrastaging. However, while it has shown high sensitivity and feasibility in low-risk [...] Read more.
Background: In endometrial carcinoma (EC) patients, sentinel lymph node (SLN) biopsy has shown the potential to reduce post-operative morbidity and long-term complications, and to improve the detection of low-volume metastasis through ultrastaging. However, while it has shown high sensitivity and feasibility in low-risk EC patient groups, its role in high-risk groups is still unclear. Aim: To assess the role of SLN biopsy through the cervical injection of indocyanine green (ICG) in high-risk groups of early-stage EC patients. Materials and methods: Seven electronic databases were searched from their inception to February 2021 for studies that allowed data extraction about detection rate and accuracy of SLN biopsy through the cervical injection of ICG in high-risk groups of early-stage EC patients. We calculated pooled sensitivity, false negative (FN) rate, detection rate of SLN per hemipelvis (DRh), detection rate of SLN per patients (DRp), and bilateral detection rate of SLN (DRb), with 95% confidence interval (CI). Results: Five observational cohort studies (three prospective and two retrospective) assessing 578 high risk EC patients were included. SLN biopsy sensitivity in detecting EC metastasis was 0.90 (95% CI: 0.03–0.95). FN rate was 2.8% (95% CI: 0.6–11.6%). DRh was 88.4% (95% CI: 86–90.5%), DRp was 96.6% (95% CI: 94.7–97.8%), and DRb was 80% (95% CI: 75.4–83.9). Conclusion: SLN biopsy through ICG cervical injection may be routinely adopted instead of systematic pelvic and para-aortic lymphadenectomy in surgical staging for high-risk groups of early-stage EC patients, as well as in low-risk groups. Full article
(This article belongs to the Special Issue Second Edition of Gynecological Cancer)
Show Figures

Figure 1

Back to TopTop